The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved a new treatment, relugolix combination therapy, for endometriosis in adult women. This therapy includes a GnRH receptor antagonist to reduce hormone levels and ease symptoms. Endometriosis affects 1 in 10 women and can cause intense pain and impact daily life. Clinical trials showed positive results, with 75% of patients experiencing pain relief. The treatment aims to address the unmet medical need for long-term relief from endometriosis symptoms. Discussions are ongoing with NICE and SMC for potential NHS availability of the therapy by 2025.
Source link
First-in-Class Endometriosis Rx Given Green Light by MHRA
